Eben Tessari - 15 Jul 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
15 Jul 2025
Net transactions value
-$3,004,964
Form type
4
Filing time
07 Aug 2025, 16:40:21 UTC
Previous filing
16 Jul 2025
Next filing
20 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tessari Eben CHIEF OPERATING OFFICER 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM /s/ Madelyn Zeylikman, Attorney-in-Fact 07 Aug 2025 0001867899

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Award $11,754 +752 +1.5% $15.63 49,915 15 Jul 2025 Direct F1
transaction KNSA Class A Ordinary Share Options Exercise $403,294 +38,928 +78% $10.36 88,843 05 Aug 2025 Direct F2
transaction KNSA Class A Ordinary Share Options Exercise $394,859 +30,444 +34% $12.97 119,287 05 Aug 2025 Direct F2
transaction KNSA Class A Ordinary Share Options Exercise $363,081 +32,710 +27% $11.10 151,997 05 Aug 2025 Direct F2
transaction KNSA Class A Ordinary Share Options Exercise $309,975 +25,896 +17% $11.97 177,893 05 Aug 2025 Direct F2
transaction KNSA Class A Ordinary Share Options Exercise $114,443 +10,636 +6% $10.76 188,529 05 Aug 2025 Direct F2
transaction KNSA Class A Ordinary Share Sale $4,583,725 -138,064 -73% $33.20 50,465 05 Aug 2025 Direct F2, F3
transaction KNSA Class A Ordinary Share Sale $18,645 -550 -1.1% $33.90 49,915 05 Aug 2025 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -38,928 -100% $0.000000 0 05 Aug 2025 Class A Ordinary Share 38,928 $10.36 Direct F2, F5
transaction KNSA Share Option Options Exercise $0 -30,444 -65% $0.000000 16,694 05 Aug 2025 Class A Ordinary Share 30,444 $12.97 Direct F2, F6
transaction KNSA Share Option Options Exercise $0 -32,710 -50% $0.000000 32,710 05 Aug 2025 Class A Ordinary Share 32,710 $11.10 Direct F2, F7
transaction KNSA Share Option Options Exercise $0 -25,896 -40% $0.000000 39,524 05 Aug 2025 Class A Ordinary Share 25,896 $11.97 Direct F2, F8
transaction KNSA Share Option Options Exercise $0 -10,636 -25% $0.000000 31,908 05 Aug 2025 Class A Ordinary Share 10,636 $10.76 Direct F2, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2025 to July 15, 2025. The acquisition of these shares was exempt pursuant to Rule 16B-3(e).
F2 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.83 and $33.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.83 and $33.98. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5 The option is fully vested and exercisable.
F6 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
F7 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.
F8 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.
F9 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.